

## Shortlist artikelen Dr. Peter Moleman Penning 2024

### 1. **Antidepressants or running therapy: Comparing effects on mental and physical health in patients with depression and anxiety disorders.**

Josine E. Verhoeven a,\* , Laura K.M. Han a , Bianca A. Lever-van Milligen a , Mandy X. Hu a , Dora ´ R ´ev ´esz b , Adriaan W. Hoogendoorn a , Neeltje M. Batelaan a , Digna J.F. van Schaik a , Anton J.L.M. van Balkom a , Patricia van Oppen a , Brenda W.J.H. Penninx a

### 2. **Original Investigation | Psychiatry Effectiveness of Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder A Randomized Clinical Trial**

Cornelis F. Vos, MD; Sophie E. ter Hark, PharmD; Arnt F. A. Schellekens, MD, PhD; Jan Spijker, MD, PhD; Annemarie van der Meij, MD; Anne J. Grotenhuis, PhD; Raluca Mihaescu, MD, PhD; Wietske Kievit, PhD; Rogier Donders, PhD; Rob E. Aarnoutse, PharmD, PhD; Marieke J. H. Coenen, PhD; Joost G. E. Janzing, MD, PhD

### 3. **Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST)**

Inge Winter-van Rossum, Mark Weiser, Silvana Galderisi, Stefan Leucht, Istvan Bitter, Birte Glenthøj, Alkomiet Hasan, Jurjen Luykx, Marina Kupchik, Georg Psota, Paola Rocca, Nikos Stefanis, Alexander Teitelbaum, Mor Bar Haim, Claudia Leucht, Georg Kemmler, Timo Schurr, the EULAST Study Group\*, Michael Davidso†, René S Kahn†, W Wolfgang Fleischhacker

### 4. **Generalizability of the Results of Efficacy Trials in First-Episode Schizophrenia: Comparing Outcome and Study Discontinuation of Groups of Participants in the Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial**

Lyliana G Nasib 1 2, Inge Winter-van Rossum 1 3, Nicolaas P A Zuithoff 4, Zimbo S R M Boudewijns 1, Stefan Leucht 5, René S Kahn 1 3

### 5. **The Relationship of Early Sleep Improvement With Response to Pharmacotherapy in Unipolar Psychotic Depression**

Cornelis F. Vos, MD,1,2 Tom K. Birkenhäger, MD, PhD,3,4 Willem A. Nolen, MD, PhD,5 Walter W. van den Broek, MD, PhD,3 Sophie E. ter Hark, PharmD,1,2 Arnt F.A. Schellekens, MD, PhD,1,2 Robbert-Jan Verkes, MD, PhD,1,2 and Joost G.E. Janzing, MD, PhD1,2

### 6. **The Direct and Long-Term Effects of Raloxifene as Adjunctive Treatment for Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Clinical Trial**

Bodily A. Brand\*,1,2, , Janna N. de Boer1,2, , Machteld C. Marcelis3,4 , Koen P. Grootens5,6 , Jurjen J. Luykx1,7,8,9,a , and Iris E. Sommer1,2,a

**7. Clonidine augmentation in patients with schizophrenia: A double-blind, randomized placebo-controlled trial**

Caitlyn Kruiper a , Iris E.C. Sommer b , Michiel Koster a , P. Roberto Bakker c,d , Sarah Durston a , Bob Oranje e,\*

**8. Towards precision dosing of aripiprazole in children and adolescents with autism spectrum disorder: Linking blood levels to weight gain and effectiveness**

Rebecca A. Hermans<sup>1,2,3</sup> | Sebastiaan D. T. Sassen<sup>1,3</sup> | Sanne Maartje Kloosterboer<sup>1,2,3</sup> | Catrien G. Reichart<sup>4</sup> | Mirjam E. J. Kouijzer<sup>5</sup> | Matthias M. J. de Kroon<sup>6</sup> | Dennis Bastiaansen<sup>7</sup> | Daphne van Altena<sup>8</sup> | Ron H. N. van Schaik<sup>9</sup> | Kazem Nasserinejad<sup>10</sup> | Manon H. J. Hillegers<sup>2</sup> | Birgit C. P. Koch<sup>1,3</sup> | Bram Dierckx<sup>2</sup> | Brenda C. M. de Winter<sup>1,3</sup>

**9. Withdrawing methylphenidate in relation to serum levels of ferritin and zinc in children and adolescents with attention-deficit/ hyperactivity disorder**

Paul T. Rosenau a,b,\* , Barbara J. van den Hoofdakker a,b , Anne-Flore M. Matthijssen a , Gigi H.H. van de Loo-Neus c , Jan K. Buitelaar c,d , Pieter J. Hoekstra a,b , Andrea Dietrich a,b

**10. Feasibility and Effect of Increasing Clozapine Plasma Levels in Long-Stay Patients With Treatment-Resistant Schizophrenia**

Jan P.A.M. Bogers, MD, MSc,<sup>1</sup> Peter F.J. Schulte, MD, PhD,<sup>2</sup> Theo G. Broekman, MSc,<sup>3</sup> and Lieuwe de Haan, MD, PhD<sup>4</sup>

**11. Treatment Response Prediction in Major Depressive Disorder Using Multimodal MRI and Clinical Data: Secondary Analysis of a Randomized Clinical Trial**

Maarten G. Poirot, M.S., Henricus G. Ruhe, M.D., Ph.D., Henk-Jan M.M. Mutsaerts, M.D., Ph.D., Ivan I. Maximov, Ph.D., Inge R. Groote, M.D., Ph.D., Atle Bjørnerud, Ph.D., Henk A. Marquering, Ph.D., Liesbeth Reneman, M.D., Ph.D., Matthan W.A. Caan, Ph.D.

**12. Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension**

Sanne Y. Smith-Apeldoorn<sup>1,9</sup>✉, Jolien K. E. Veraart<sup>1,2,9</sup>, Jeanine Kamphuis<sup>1</sup> , Jan Spijker<sup>3,4</sup>, Annemarie van der Meij<sup>3</sup> , Antoinette D. I. van Asselt<sup>5,6</sup>, Marije aan het Rot<sup>7,8</sup> and Robert A. Schoevers<sup>1,8</sup>

**13. Gender differences in the response to antipsychotic medication in patients with schizophrenia: An individual patient data meta-analysis of placebo-controlled studies**

Bram W.C. Storosum a,\* , Taina Mattila b , Tamar D. Wohlfarth b , Christine C. Gispen-de Wied b , Kit C.B. Roes b,c , Wim van den Brink a , Lieuwe de Haan a,d , Damiaan A.J.P. Denys a,e , Jasper B. Zantvoord a

**14. Pneumonia Risk, Antipsychotic Dosing, and Anticholinergic Burden in Schizophrenia**

Jurjen J. Luykx, MD, PhD; Christoph U. Correll, MD; Peter Manu, MD; Antti Tanskanen, PhD; Alkomiet Hasan, MD; Jari Tiihonen, MD, PhD; Heidi Taipale, PhD

**15. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: Can the regulations be relaxed?**

Peter F.J. Schulte a,b,\* , Selene R.T. Veerman a,b , Bert Bakker b,1 , Jan P.A.M. Bogers b,c , Amy Jongkind b,d , Dan Cohen a,b